Evidence map›Paper›PMID 37538192›Full record

ArticleClinical & translational immunology2023

Inverse relationship between

Tomotaka Ugai, Takashi Shimizu, Hidetaka Kawamura, Satoko Ugai, Yasutoshi Takashima, Genki Usui, Juha P Väyrynen, Kazuo Okadome, Koichiro Haruki, Naohiko Akimoto and 13 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical & translational immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Microbiota in cancer: current understandings and future perspectives.Signal transduction and targeted therapy · 2026
    Review
  2. Review
  3. Article
  4. Review
  5. Unraveling the Role ofCancers · 2025
    Review
  6. Article
  7. Potential and application ofFrontiers in microbiology · 2025
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 5 institutions in 3 countries.

Tomotaka UgaiProgram in MPE Molecular Pathological Epidemiology, Department of Pathology Brigham and Women's Hospital and Harvard Medical School Boston MA USA.
Takashi ShimizuProgram in MPE Molecular Pathological Epidemiology, Department of Pathology Brigham and Women's Hospital and Harvard Medical School Boston MA USA.
Hidetaka KawamuraProgram in MPE Molecular Pathological Epidemiology, Department of Pathology Brigham and Women's Hospital and Harvard Medical School Boston MA USA.
Satoko UgaiDepartment of Epidemiology Harvard T.H. Chan School of Public Health Boston MA USA.
Yasutoshi TakashimaProgram in MPE Molecular Pathological Epidemiology, Department of Pathology Brigham and Women's Hospital and Harvard Medical School Boston MA USA.
Genki UsuiProgram in MPE Molecular Pathological Epidemiology, Department of Pathology Brigham and Women's Hospital and Harvard Medical School Boston MA USA.
Juha P VäyrynenProgram in MPE Molecular Pathological Epidemiology, Department of Pathology Brigham and Women's Hospital and Harvard Medical School Boston MA USA.
Kazuo OkadomeProgram in MPE Molecular Pathological Epidemiology, Department of Pathology Brigham and Women's Hospital and Harvard Medical School Boston MA USA.
Koichiro HarukiProgram in MPE Molecular Pathological Epidemiology, Department of Pathology Brigham and Women's Hospital and Harvard Medical School Boston MA USA.
Naohiko AkimotoProgram in MPE Molecular Pathological Epidemiology, Department of Pathology Brigham and Women's Hospital and Harvard Medical School Boston MA USA.
Yohei MasugiProgram in MPE Molecular Pathological Epidemiology, Department of Pathology Brigham and Women's Hospital and Harvard Medical School Boston MA USA.
Annacarolina da SilvaDepartment of Pathology and Laboratory Medicine Weill Cornell Medicine New York NY USA.
Kosuke MimaDepartment of Gastroenterological Surgery, Graduate School of Medical Sciences Kumamoto University Kumamoto Japan.
Xuehong ZhangChanning Division of Network Medicine, Department of Medicine Brigham and Women's Hospital and Harvard Medical School Boston MA USA.
Andrew T ChanChanning Division of Network Medicine, Department of Medicine Brigham and Women's Hospital and Harvard Medical School Boston MA USA.
Molin WangDepartment of Epidemiology Harvard T.H. Chan School of Public Health Boston MA USA.
Wendy S GarrettDepartment of Medical Oncology Dana-Farber Cancer Institute and Harvard Medical School Boston MA USA.
Gordon J FreemanDepartment of Medical Oncology Dana-Farber Cancer Institute and Harvard Medical School Boston MA USA.
Jeffrey A MeyerhardtDepartment of Medical Oncology Dana-Farber Cancer Institute and Harvard Medical School Boston MA USA.
Jonathan A NowakProgram in MPE Molecular Pathological Epidemiology, Department of Pathology Brigham and Women's Hospital and Harvard Medical School Boston MA USA.
Mingyang SongDepartment of Nutrition Harvard T.H. Chan School of Public Health Boston MA USA.
Marios GiannakisDepartment of Medical Oncology Dana-Farber Cancer Institute and Harvard Medical School Boston MA USA.
Shuji OginoProgram in MPE Molecular Pathological Epidemiology, Department of Pathology Brigham and Women's Hospital and Harvard Medical School Boston MA USA.ORCID https://orcid.org/0000-0002-3909-2323
Brigham and Women's Hospital · USHarvard University · USBroad Institute · USCornell University · USKumamoto University · JP

Funding

Transgenic/KnockoutP01AI056299 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI BLAZAR, BRUCE R · 2003 to 2023
$42.5M
Gut microbiota and inflammatory monocytes in colorectal cancerR01CA154426 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI GARRETT, WENDY S. · 2011 to 2025
$5.2M
Coffee and metabolites modulating the gut microbiome for improved colorectal cancer survivalR01CA263776 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Mingyang Song · 2022 to 2026
$3.3M
The Gut Microbiome, Lifestyle, and Colorectal NeoplasiaU01CA261961 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Mingyang Song · 2022 to 2026
$3.0M
NCI NIH HHS R01 CA154426NCI NIH HHS R01 CA263776NCI NIH HHS U01 CA261961NIAID NIH HHS P01 AI056299
6 · The paper itself

Abstract

Objectives: The CD274 (programmed cell death 1 ligand 1, PD-L1)/PDCD1 (programmed cell death 1, PD-1) immune checkpoint axis is known to regulate the antitumor immune response. Evidence also supports an immunosuppressive effect of Methods: We assessed tumor CD274 expression by immunohistochemistry and Results: Conclusions: Tumor CD274 expression level was inversely associated with the amount of

Indexed as

colorectal neoplasmimmune toleranceimmunologymicrobiologymolecular pathological epidemiology

Identifiers

PMID37538192
PMCPMC10394676
OpenAlexW4385500231

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.